Laminin-α1β1γ1 (LM-111) has previously been used as an effective therapy in pre-clinical models for the treatment of muscular dystrophies [48-50], indicating that LAM may improve the muscle microenvironment and increase muscle repair in pathological conditions where attachment of muscle fibers to the basal lamina is impaired. This evidence concerns the gene LAMB2 and muscular dystrophy.